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Abstract In order to assess the characteristics of malig-
nant breast lesions those were not detected during screen-
ing by MR imaging. In the Dutch MRI screening study
(MRISC), a non-randomized prospective multicenter study,
women with high familial risk or a genetic predisposition
for breast cancer were screened once a year by mammog-
raphy and MRI and every 6 months with a clinical breast
examination (CBE). The false-negative MR examina-
tions were subject of this study and were retrospectively
reviewed by two experienced radiologists. From November
1999 until March 2006, 2,157 women were eligible for
study analyses. Ninety-seven malignant breast tumors were
detected, including 19 DCIS (20%). In 22 patients with a
malignant lesion, the MRI was assessed as BI-RADS 1 or
2. One patient was excluded because the examinations
were not available for review. Forty-three percent (9/21) of
the false-negative MR cases concerned pure ductal carci-
noma in situ (DCIS) or DCIS with invasive foci, in eight of
them no enhancement was seen at the review. In six
patients the features of malignancy were missed or misin-
terpreted. Small lesion size (n = 3), extensive diffuse
contrast enhancement of the breast parenchyma (n = 2),
and a technically inadequate examination (n = 1) were
other causes of the missed diagnosis. A major part of the
false-negative MR diagnoses concerned non-enhancing
DCIS, underlining the necessity of screening not only with
MRI but also with mammography. Improvement of MRI
scanning protocols may increase the detection rate of
DCIS. The missed and misinterpreted cases are reflecting
the learning curve of a multicenter study.
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Introduction
Breast cancer is by far the most prevalent malignancy in
women, with a high incidence especially in Europe and
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North America. The cumulative lifetime risk of breast
cancer for Dutch women is approximately 13% [1]. A
positive family history for breast cancer or a germ line
BRCA1 or BRCA2 mutation increases the risk of devel-
oping breast cancer considerably. The estimated life time
risk for BRCA1/2 mutation carriers is 50–85% [2]. Options
to reduce the risk of breast cancer related death are pro-
phylactic surgery (including prophylactic mastectomy and/
or bilateral salpingo-oophorectomy (PBSO)), chemopre-
vention, or intensive surveillance.
Women with a strong family history are more likely to
develop breast cancer at young age. Because of higher
breast density at younger ages, screening with mammog-
raphy will be less effective. Mammographic sensitivity for
breast cancer declines significantly with increasing breast
density (in the large study of Kolb et al. [3] from 98 to 48%
for the densest breasts). Apart from a higher breast density
it appeared that, especially in BRCA1/2 mutation carriers,
also a higher growth rate and aspecific mammographic
characteristics of the tumors contribute to a lower sensi-
tivity [4–7]. Because of the consistently high sensitivity of
MRI of the breast in diagnostic settings, with values
between 90 and 100% [8–10], the role of contrast-enhanced
MRI of the breast in screening of high-risk women was
investigated. The first results of screening high-risk women
with MRI were promising: MRI detected cancers still
occult at mammography and not yet clinical manifest
[11–14].
The published results of multiple studies confirm the
effectiveness of MRI in screening of women at high
familial risk. In five prospective studies [15–19], 3,571
women were screened with contrast-enhanced MR imaging
and mammography, and with ultrasound in three of five
studies. The pooled sensitivity for mammography was
40%, in comparison to 81% for MRI [20]. The detected
cancers in 168 patients were small: 49% B10 mm diame-
ter, and only 19% of invasive cancers were associated with
lymph node involvement [20]. Similar figures were found
in the review of Warner et al. [21] who evaluated 11 pro-
spective non-randomized studies in which MRI and
mammography were used to screen women at very high
risk for breast cancer (not only women with high familial
risk). In their meta-analysis, the sensitivity of mammog-
raphy and MRI was 39 and 77%, respectively (at a cut-off
value of BI-RADS C 3).
Despite the excellent contribution of contrast-
enhanced MRI in screening of women at high familial
risk, MRI depicts not all cancers. In the present study,
we asses the characteristics of malignancies not detec-
ted by MR imaging in the Dutch MRI screening study
(MRISC study) and try to identify possible sources of
error.
Methods
In the Dutch MRISC study, a non-randomized prospective
multicenter study, women with high familial risk or a
genetic predisposition for breast cancer were screened once
a year by mammography and MRI and every 6 months
with a clinical breast examination [15].
The women were recruited from six centers with familial
breast cancer clinics. At the start of the MRISC study in
1999, in five of the six centers there was experience with
breast MR imaging in a diagnostic population and variable
experience in a screening setting. In one center breast MR
imaging started short time before beginning of the study.
This center was coached intensively.
In all six centers dynamic contrast-enhanced MRI was
performed on a 1.5 Tesla system. The MR units were, in
five of the six centers, purchased from Siemens Medical
Solutions (Erlangen, Germany) and in one center from
Philips Medical Systems (Best, The Netherlands). All
patients were investigated in prone position with the
breasts pending in a dedicated double breast surface coil.
Premenopausal women were scanned on the day 5–15 of
the menstrual cycle. Before scanning venous access was
established in a cubital vein through which a bolus of
contrast material (0.1 mmol per kg bodyweight or 15 ml
gadolinium chelate) was administered using an automated
injector at 2 ml/s followed by 20 ml saline flush at the
same injection rate. Gradient echo T1-weighted series were
made before and five times after contrast administration.
Subtraction images were obtained with the use of a soft-
ware subtraction function. All MRI examinations were
evaluated on a dedicated breast MRI workstation.
At the start of the study in 1999, a three dimensional fast
low-angle shot (FLASH 3D) was used before and five
times after contrast administration. The parameters of the
dynamic series were: FOV 320 mm, transversal slices of
1.5 mm thickness, pixel size 1.67 mm 9 1.25 mm, scan
time 90 s, 1 acquisition, TR = 8.1 ms, TE = 4.0 ms, flip
angle 20. During the study, the MR units were upgraded
and scanning protocols improved. Mainly spatial resolution
was improved while maintaining the dynamic series at time
intervals of 90 s. At the beginning of the study all centers,
except one, performed mammography on conventional
units. Through the years the other five centers also pro-
ceeded to digital mammography. Standard oblique and
craniocaudal projections were obtained with additional
views if necessary.
Mammography and MR examination were scored
according to the Breast Imaging Reporting and Data Sys-
tem (BI-RADS) [22] with independent readings. An
imaging test with BI-RADS score 3 (‘‘probably benign
finding’’), O (‘‘need additional imaging evaluation’’), 4
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(‘‘suspicious abnormality’’), and 5 (‘‘highly suggestive of
malignancy’’) was defined as positive, because in these
cases additional examination was indicated. A BI-RADS
score of 1 (‘‘negative’’) and 2 (‘‘benign finding’’) were
defined as negative.
Participants were divided into three subgroups accord-
ing to their estimated cumulative lifetime risk (CLTR) of
developing breast cancer: carriers of the BRCA1 or BRCA
2 or other mutations (50–85% CLTR), a high-risk group
(30–50% CLTR) and a moderate-risk group (15–30%
CLTR).
A screen-detected malignancy was found during a
screening round by MR imaging, mammography, or CBE
or any combination of these methods. For mammography
and MRI, we calculated the sensitivity defined as the per-
centage of malignancies with a positive test result. The
overall results of the main analysis of the MRSIC study (to
be published separately) may show slightly different
numbers due to minor differences in patient groups. Can-
cers detected in specimens from prophylactic mastectomy
were excluded from analysis. An interval carcinoma was
defined as a malignancy detected between two screening
rounds. A false-negative MRI case was defined as a biopsy
proven malignancy while the MRI examination, performed
within 1 year prior to detection, was evaluated as negative
(BI-RADS 1 or 2). The false-negative MR cases were
subject of this study and were retrospectively evaluated.
Review of the false-negative MRI examinations was done
by two experienced radiologists reaching consensus. In the
MRISC study, the MR examinations were evaluated blin-
ded to the information of mammography. This review was
done with all clinical and diagnostic information about
location, size, and histology of the malignancy available to
the two radiologists (IMO and CB or CL).
In case there was no lesion or suspicious enhancement
visible in retrospect, the diagnostic quality of the MR
examination was assessed as possible cause of a false-
negative diagnosis. The radiologists assessed the diagnostic
quality of the MRI by evaluating motion artefacts, inade-
quate infusion and timing of contrast material, and the
degree of background enhancement.
In case malignancy could be identified in retrospect, it
was scored as missed or misinterpreted. The lesion (an
enhancing mass or non-mass like enhancement) at the MRI
was evaluated on a dedicated MRI workstation. The
reviewing radiologists performed assessment of lesion size,
morphology, and enhancement kinetics.
Results
From November 1999 to March 2006, 2,157 women were
eligible for study analyses, including 599 proven carriers of
a BRCA1 (n = 422) or BRCA2 (n = 172) mutation or
PTEN/TP53 (n = 5), 1,069 women in the high-risk group
and 489 in the moderate-risk group.
Ninety-seven malignant breast tumors were detected in
93 patients, including 19 DCIS (20%). Seventy-eight can-
cers were screen detected, 13 were interval cancers and six
malignancies were found at prophylactic mastectomy. The
latter six malignancies are excluded for analysis of sensi-
tivity. The 93 patients however, did not all have a complete
screening round previous to the detection of the malig-
nancy. Clinical examination, MRI and/or mammography
were not always all performed. Eighty-one of the 93
patients underwent mammography before the detection of
breast cancer. In 36 cases, mammography demonstrated the
malignancy: sensitivity 44% (36/81).
Seventy-six patients underwent a screening round with
MRI examination before the detection of a malignancy. In
22 of the 76 patients, the MRI was assessed as BI-RADS 1
or 2. The overall sensitivity of MRI was 71% (54/76). The
sensitivity for invasive carcinoma was 78% (49/63), for
pure DCIS 39% (5/13). One patient was excluded from the
review because the MR examinations were not available
anymore. This concerned a small invasive focus with
DCIS. Therefore, 21 patients from the MRISC study with a
biopsy proven malignancy and a MR examination scored
as BI-RADS 1 or 2, were included in this study.
Clinical and radiological data of malignancies occult
on MRI, also at the review
Also in retrospect, no enhancing mass or non-mass like
enhancement could be identified in 12 of the 21 MRI
examinations (Table 1). Except for one inadequate exam-
ination (Table 1, case 12), the BI-RADS classification
remained 1, also at the review. Eight of these cases, in
which no explanation for the false-negative diagnosis was
found, were non-palpable mammographically detected
DCIS. Seven of them were pure DCIS, and one concerned
DCIS with an invasive focus of 4 mm. Mean tumor size
was 20 mm (range 7–50 mm) (Table 1, case 1–8).
The ninth case (Table 1, case 9) in which no explanation
was found for not showing the lesion at the screening,
concerned an interval carcinoma in a BRCA1 carrier,
which became evident 10 months after imaging. It was a
12-mm invasive ductal adenocarcinoma, grade 3, probably
with a high growth rate.
In one patient (Table 1, case 10) small size and exten-
sive diffuse contrast enhancement of the breast paren-
chyma were probably reasons for false negativity. This
woman underwent lumpectomy because of mastopathic
complaints. In the lumpectomy specimen, accidentally a
5-mm grade 1 invasive ductal carcinoma was discovered at
histological examination.
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In a 36-year-old women with a CLTR of 30–50%, who
presented with a palpable mass 10 months after screening,
intensive diffuse enhancement of the breast parenchyma
prevented the detection of the malignancy (Table 1, case 11).
At the review no mass or suspicious contrast enhancing
areas could be distinguished. Also, the mammography was
re-evaluated as normal. A 15-mm invasive ductal carci-
noma grade 2 was found.
In case 12 (Table 1), a multifocal invasive carcinoma
with surrounding DCIS was not detected on the MR
examination with serious motion artefacts. This inadequate
MR examination should have been repeated. Mammogra-
phy and ultrasound only revealed the largest invasive
lesion. The additional surrounding DCIS was not visible on
the mammogram.
Clinical and radiological data of malignancies
visible at the review
In 9 of the 21 reviewed cases an abnormality was observed
in retrospect, which changed the BI-RADS classification of
the MRI (Table 2). Four times it was changed to BIRADS
3, once to BIRADS 4 and also four times into BI-RADS 5.
Retrospectively in 8 cases, a mass was seen and in one case
a non mass-like segmental enhancement.
– In three of these nine cases (Table 2, case 1–3) small
round lesions, 4 or 5 mm diameter, with type 2 or 3
time–intensity curves could be distinguished. At the
review, the BI-RADS classification changed from 1 to
3. In these three patients the lesions became clinically
evident as interval carcinoma. Two of the three patients
were BRCA1 mutation carriers.
– In three patients (Table 2, case 4–6) an enhancing mass
or area was described but incorrectly interpreted as
benign lesions or benign enhancing breast tissue. At the
review, the BI-RADS classification became 3, 4, and 5,
respectively.
– In three other patients, a suspicious abnormality was
missed (Table 2, case 7–9). The MR examination of one
of them, a BRCA1 mutation carrier, showed a 9-mm
round, well defined lesion however with rim enhance-
ment and wash-out on the time–intensity curves. This
lesion was classified as BI-RADS 5 at the review and
became palpable during pregnancy as a 45-mm invasive
ductal carcinoma, grade 3. The screening mammogram
was again evaluated as normal (Table 2, case 7). Another
BRCA1 mutation carrier presented 7 months after
screening with an interval carcinoma. On her MR
examination, a 15-mm BI-RADS 5 lesion was missed.
The screening mammogram was not available for review
(Table 2, case 8). The third missed lesion (Table 2, case
9) was a 10-mm lobulated mass with rim enhancement.
Time–intensity curves showed a type 3 curve. The mass
was evaluated as BI-RADS 5. It proved to be a 12-mm
invasive ductal adenocarcinoom grade 2 with extensive
DCIS, grade 2. The DCIS was occult on MR but visible
on mammography.
Table 1 Clinical and radiological data of 12 malignancies occult on MRI, also at the review
Risk
category
Age at
diagnosis
Histology Tumor size PA Palpable XM review
BIRADS
MR review: reason
of FN diagnosis
1 CLTR 30–50% 45 DCIS grade 1 18 mm No 0 ? 4 None
2 CLTR 15–30% 48 DCIS grade 2 10 mm No 0 ? 4 None
3 CLTR 15–30% 60 DCIS grade 3 8 mm No 4 ? 4 None
4 CLTR 15–30% 31 DCIS grade 2 17 mm No 4 ? 4 None
5 BRCA1 42 DCIS grade 1 50 mm No 4 ? 4 None
6 BRCA2 36 DCIS grade 3 7 mm No 4 ? 4 None
7 BRCA1 32 DCIS grade 3 20 mm No 4 ? 4 None
8 BRCA2 35 Foci of IDC and
DCIS grade 3
4 mm, and
28 mm
No 4 ? 4 None
9 BRCA1 53 IDC, grade 3 12 mm Yes, interval 10 months
after screening
1 ? 1 None
10 CLTR 30–50% 49 IDC, grade 1 5 mm No, found with
lumpectomy performed
for mastopathy
2 ? 2 Small size, intensive
enhancement
11 CLTR 30–50% 36 IDC, grade 2 15 mm Yes, interval 10 months
after screening
na Intensive enhancement
12 BRCA2 36 Two lesions IDC
and DCIS grade 3
20 mm and
10 mm, size DCIS na
No 4 ? 4 Inadequate examination
BI-RADS 1 ? 0
FN false negative, XM mammography, PA pathology, DCIS ductal carcinoma in situ, IDC invasive ductal adenocarcinoma, na not available,
CLTR cumulative life time risk, ? change of BI-RADS category from study to review
402 Breast Cancer Res Treat (2010) 119:399–407
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Discussion
Conform to our previous results and the results from other
prospective studies [15–19], the sensitivity of contrast-
enhanced MR imaging for breast cancer screening in
women with a familial or genetic predisposition is signif-
icantly higher compared to the sensitivity of mammogra-
phy. However, MRI demonstrated not all malignancies.
We reviewed the examinations of 21 of the 97 cancers in
the MRISC study who were not detected with MRI. Eight
of these 21 undetected cancers were pure DCIS. All but one
were also at the review classified as BI-RADS 1 while no
enhancing masses or foci or non mass-like enhancement
could be discriminated on the MR examination. Also, one
case of DCIS with an invasive focus was occult on MRI, in
the study as well at the review. In the mid-term analysis of
the MRISC study, the sensitivity for the detection of pure
DCIS is 39% (5/13) for MR imaging and 73% (11/15) for
mammography. Four of the five intraductal cases visual-
ized by MR were mammographically occult. In our study,
mammography and MRI were complimentary for the
detection of DCIS, with a higher sensitivity for mam-
mography. Pooling together the 40 cases of DCIS detected
in the mid-term analysis of the MRISC study and of the
Canadian, English, German, and Italian screening studies
[16–19], MRI has a sensitivity of 60% (23/38) (two
patients with DCIS did not underwent MR). The sensitivity
of mammography for DCIS is 60% (24/40) while 10 of the
40 (25%) cases were detected only by mammography. In
our opinion, therefore, it is too early to leave out mam-
mography from ongoing screening programs and current
guidelines for women at increased familial breast cancer
risk. The MRI sensitivity for DCIS in the present study is
conform to the MARIBS study [17], where two of the six
DCIS were diagnosed with MR (sensitivity 33%), but
lower than reported in the other screening studies. Warner
et al. [16] detected four out of six DCIS with MRI (sen-
sitivity 67%), while Kuhl et al. [18] diagnosed eight out of
nine intraductal cancers with MRI (sensitivity 89%). In the
study of Sardanelli et al. [19] all four cases of DCIS were
diagnosed with MRI (sensitivity 100%). Remarkable
results are obtained in a prospective observational study of
Kuhl et al. [23] in which 92% of DCIS cases were diag-
nosed by MRI, and only 56% by mammography. The
above mentioned study of Kuhl et al. has, however, a
totally different study population: in the Dutch MRISC
study only asymptomatic women with a familial risk of
breast cancer (with 28% BRCA1/2 mutation carriers) were
included while in the study of Kuhl et al. only eight (5%)
women underwent MR as a screening examination for
familial breast cancer. In contrast with the MRISC study,
patients with an abnormal mammogram as well as patients
with clinical symptoms or a history of previous breast
cancer were included. Furthermore, the study was con-
ducted in a single center, with a high level of expertise in
performing and reading breast MR examinations. These
factors might have influenced the finding of a high sensi-
tivity of MRI for DCIS. Schouten van der Velden et al.
[24] evaluated the literature from 1995 till 2008 on this
subject and found that in these 30 studies the detection rate
of DCIS by MRI ranged from 38 to 100%. Consistent with
the results of Kuhl et al. [23] also other studies achieved
high sensitivities for the detection of DCIS with MRI [25–
28]. However, also in these studies most of the patients
underwent MR for evaluation of known or suspected breast
cancer, sometimes clinically evident. In some studies also
cases of DCIS with microinvasion were included. Although
the improvement of MR technique through the years with
emphasis on high spatial resolution will have improved the
detection of DCIS, the results of these studies certainly
reflect a patient selection.
The detection of DCIS on MRI depends on three factors:
tumor neovascularization, scanning technique, and MR
presentation and recognition. The growth of a solid tumor
above a diameter of a few millimeters is dependent of
formation of new vascular structures. This neovasculari-
zation, with an increased permeability of the microvessels
and high vascular density, is the prerequisite for contrast
agent pooling in and around malignant lesions. Also, DCIS
is capable of inducing neovascularization. The process of
angiogenesis is stimulated by growth factors such as vas-
cular endothelial growth factor (VEGF) and platelet-
derived endothelial growth factor/thymidine phosphorylase
(PD-ECGF/TD) released into the stroma by tumor and
immune cells [29, 30]. Vogl et al. [29] found PD-ECGF/TP
to be present in all cases of DCIS, without a significant
correlation with the DCIS subtype. In the study of Guidi
et al. [30], in 84% of the cases of DCIS microvessel density
was more prominent than in benign tissue. The degree of
angiogenesis was variable and strongly related to the
degree of vascular endothelial growth factor (VEGF)
expression. High grade DCIS was more often associated
with a strong VEGF expression than low grade lesions,
which was also observed by Vogl et al. [29]. However,
these differences in VEGF expression between low grade
and high grade lesions were not statistically significant.
The variable degree of angiogenesis in DCIS will explain
partly why not all cases will be visible on MR. In our series
the seven cases pure DCIS without enhancement concerned
high grade as well as low grade lesions. Also, Santamaria
et al. [31] observed that the nuclear grade of DCIS was not
significantly related to the degree of enhancement or the
time–intensity curve. Facius et al. [27], on the contrary,
who evaluated retrospectively the MR characteristics of 74
cases of pure DCIS, found contrast enhancement similar to
glandular tissue only in low grade DCIS. This is in
404 Breast Cancer Res Treat (2010) 119:399–407
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concordance with the results of Kuhl et al. [23] who found
that the sensitivity of MRI increased with higher nuclear
grade, detecting 98% of high grade DCIS and 85% of low
and intermediate grade DCIS.
The detection of DCIS requires a high spatial resolution
scanning technique, ideally with a submillimeter pixel size
in each in-plane direction and a slice thickness of 1–3 mm
[32, 33]. DCIS is confined to the ducts and the ducts are
surrounded by normal tissue. Image voxels represent an
average intensity of the components including the voxels.
When larger voxels are used the ‘‘partial volume averaging
effect’’ may prevent reliable detection the often smaller
structures of DCIS. Most of the non-enhancing DCIS cases
of the MRISC study concerned MRI examinations made in
the beginning years of the study. Insufficient spatial reso-
lution might have been an important factor of not depicting
DCIS.
Could false-negative diagnoses have been avoided?
A technically inadequate examination prevented the right
diagnosis in one patient (Table 1, case 12), which could
have been avoided by repeating the examination.
Although the MR examinations were planned preferably
between day 5 and 15 of the menstrual cycle, intensive
back ground contrast enhancement was seen regularly. By
repeating the examination of all premenopausal patients
with intensive contrast enhancement in accordance with the
menstrual cycle, the chance of detecting the malignancy
would have been higher (Table 1, case 10,11), although
this will not be achievable.
Three false-negative MR diagnoses concerned small
lesions with a type 2 or 3 curve in young high-risk patients
(Table 2, case 1–3) who presented later with an interval
carcinoma. These cases indicate that small lesions with a
type 2 or 3 curve in young high-risk patients and especially
in BRCA1 mutation carriers, with more rapidly growing
tumors [34], cannot be neglected (Fig. 1). Short-interval
follow-up consisting of second look ultrasound and/or MR
examination has to be considered. However, this will
negatively influence the false positive fraction and conse-
quently increase additional work-up and number of
biopsies.
Contrary to the MRISC study, in the MARIBS study
[17] all MR as well as the mammographic examinations
were double red. The effect of double reading of the MR
examinations was evaluated in a population of screening
examinations mixed with symptomatic cases [35]. The
double reading policy achieved a higher sensitivity: 84%
with single reading and 91% with double reading, but at
costs of higher recall and biopsy rate. In our study, double
reading probably could have prevented that five malig-
nancies, evaluated at the review as BI-RADS 4 and 5
lesions, were not detected (Table 2, cases 4, 5, 7, 8, 9). An
alternative to double reading would be computer-aided
diagnosis (CAD). During this period of the MRISC study
CAD was available in only one center.
In contrast with single center studies with only a few
readers, the MRISC study is a multicenter study with a
group of radiologists with varying levels of experience.
The misinterpretation of the MR examination in three
malignancies (Table 2, cases 4–6) as well as the three
Fig. 1 a–f Example of missed
malignancy in a 40-year old
BRCA 1 gene carrier due to
small size at time of screening
but visible at review. Shown are
subtracted MR images of initial
enhancement in sagital (a, d),
axial (b, e) and coronal (c, f)
planes at time of screening
(upper row a-c) and at time of
diagnosis (lower row d-f). Four
months after screening there is
palpable malignancy of 15 mm
showing as a irregular mass
with rim-enhancement (d, e, f).
Retrospectively a small (4 mm)
mass with wash out is seen at
the screening MRI (a, b, c)
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missed carcinomas (Table 2, case 7–9) reflect the learning
curve of a multi-center study.
Conclusion
More than 40% of the false-negative MR diagnoses
involved pure DCIS and DCIS with invasive foci without
enhancement and therefore a correct false-negative MR
diagnosis, indicating a lower sensitivity of MRI for DCIS.
In the MRISC study, mammography and MRI were com-
plementary for the detection of DCIS, underlining the
necessity of screening not only with MRI but also with
mammography.
Other causes of a false-negative MR diagnosis were
inadequate examination, small lesion size and extensive
background enhancement (about 30%). In young high-risk
patients, and especially in BRCA1 mutation carriers, short-
term follow-up has to be considered for small lesions. The
missed or misinterpreted cases, in about 30% the reason of
a false-negative diagnosis, are reflecting the learning curve
of a multicenter study.
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